To explore the potential clinical anti-
tumor roles of Bacillus subtilis fmbJ-derived
fengycin on cell growth and apoptosis in
colon cancer HT29 cell line.Fengycin was extracted from Bacillus subtilis fmbJ and detected using HPLC. The effects of different concentration of
fengycin on colon cell HT29 cell activity at different time points were analyzed using MTT assay. ROS level in colon HT29 cells affected by
fengycin was detected using
DCFH-DA method, followed by measuring the effects of
fengycin on HT29 cell apoptosis and cell cycle by flow cytometry. The effects of
fengycin on Bax/Bcl-2, CDK4/
cyclin D1,
Caspase-6 and
Caspase-3 expressions in HT29 cells were analyzed using western blot. Also,
mRNA levels of Bax/Bcl-2 and CDK4/
cyclin D1 in HT29 cells affected by
fengycin were analyzed using qRT-PCR.Compared with controlss, 20 μg/mL of
fengycin performed an inhibit role on HT29 cell growth of at 3 day (P<0.05), and high dose of
fengycin showed more excellent effect on inhibiting HT29 cell growth with time increasing. Besides,
fengycin could induce HT29 cell apoptosis and affect the cell cycle arrest at G1. ROS level in HT29 cells treated by
fengycin was significantly increased compared with that in control group (P<0.05). Western blot analysis showed that after being treated with
fengycin, Bax,
Caspase-3, and
Caspase-6 expressions were increased, however, Bcl-2, and CDK4/
cyclin D1 expressions were decreased (P<0.05).Our study suggested that
fengycin may play certain inhibit roles in the development and progression of
colon cancer through involving in the cell apoptosis and cell cycle processes by targeting the Bax/Bcl-2 pathway.